The IQVIA Institute for Human Data Science Study has developed a specific forecast for these new biosimilar molecules in oncology. The majority of the savings will be from three top-selling ...

Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, ...

Biosimilars could save European and US healthcare systems billions - but more needs to be done to maximise their benefits, writes Richard Staines. Biosimilars are becoming an ever-greater part of ...

Joshua Cohen is a Boston-based writer who covers health policy. Biosimilars offer clinically effective treatment alternatives to branded reference drugs at a lower cost. These products are making ...

Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey ...

As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially available in the U.S. It is the first and thus far only therapeutically interchangeable Humira-referenced biosimilar approved by ...

However, biosimilars are complex, large molecules that are challenging to characterize. To win approval, companies must present comprehensive data showing that the biosimilar is comparable to the ...

To pave a pathway to producing a biosimilar version of atezolizumab, Mehmet Inan, PhD, director of the Izmir Biomedicine and Genome Center in Turkey, and his colleagues developed a bioprocess for ...

Less than a decade since it secured its first FDA approval for a biosimilar, Amgen’s portfolio of the copycat drugs is growing and making strong contributions to the company’s top line.

The US Food and Drug Administration (FDA) has approved Avtozma (tocilizumab-anoh) as a biosimilar of the original reference biologic tocilizumab (Actemra), according to a January 30 announcement ...

In accordance with the biosimilar guidelines of NMPA ... a diversified and high-quality product pipeline covering over 50 molecules and has continued to explore immuno-oncology combination ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.